Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Intra-Cellular to $66 from $72 and keeps a Buy rating on the shares. The analyst came away from Intra-Cellular’s Q4 report "somewhat mixed." The firm remains encouraged by fundamental strength in Caplyta’s performance and a 2023 revenue guide that topped estimates. However, the announcement of a new Phase 3 major depressive disorder study for Caplyta comes as a negative surprise, raising concerns around potential success in the two ongoing Phase 3 studies reading out within the next 12-15 months, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- Intra-Cellular reports Q4 EPS (45c), consensus (59c)
- FFJ short Intra-Cellular, says users reporting ‘particularly toxic side effect’
- Intra-Cellular short report concerns ‘unwarranted,’ says RBC Capital
- Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast